Leading the Way in Life Science Technologies

GEN Exclusives

More »

November 15, Vol. 29, No. 20

  • Feature Articles

    • Flow Cytometry's Expanding Niche
    • Richard A. Stein
    • Cell population heterogeneity consistently emerges as an interesting and biologically relevant feature of biological systems Nevertheless, many experimental tools are informative only about entire populations While this level of inquiry is fundamental to our understanding of many phenomena governing the ... more »
    • Taking Multiplexing to the Next Level
    • K. John Morrow Jr.
    • Multiplexing technologies are essential for the rapid screening of large numbers of samples in proteomic and genomic profiling Tool providers are increasingly offering new solutions that feature ramped-up speed and efficiency Other advances include disposable labware with improved plates for ... more »
    • Strategies for Companies Targeting GPCRs
    • James Netterwald, Ph.D.
    • In the organism, communication occurs at both the macro and the micro level At the micro level—inside the cell—communication occurs between proteins relaying messages along signal-transduction pathways from both the internal and external to various compartments within the cell through ... more »
    • Head Start Boosts Value of Stability Testing
    • Vicki Glaser
    • Maximizing and validating the stability of a drug is critical throughout its life cycle, beginning in the development phase of an active pharmaceutical ingredient (API), continuing through the final formulation process, and following commercialization as part of post-marketing product analysis... more »
  • Columns

    • Cracking Down on Misinformation
    • Bruce Mackler
    • FDA reads your press releases, and it reviews your promotional materials and websites It doesn’t just give them a cursory glance either, it scrutinizes them As a result, biotech/biopharma companies are advised to fight the urge to dwell on or ... more »
    • NBS Experiences Post-Acquisition Growth
    • Carol Potera
    • About two years ago, Eppendorf  acquired New Brunswick Scientific (NBS) Known for shakers, fermentors, bioreactors, incubators, and freezers, NBS continues to operate under its own name, and the staff and management have remained largely intact... more »
    • Transfection Market Clamors for Silver Bullet
    • Jonathan Witonsky
    • Transfection of nucleic acids into cells is often cited as users’ rate-limiting step in numerous biomedical research and bioproduction workflows Accordingly, the burgeoning markets that surround biopharmaceuticals, RNA interference screening, and stem cell research are limited by the lack of ... more »
    • Developments in Focused Kinase Libraries
    • Richard Hill
    • Chemical libraries have long been a mainstay in the search for new pharmaceutical compounds, and they have been created using many different paradigms Vast diverse collections of unique compounds have been screened at high throughput to find appropriate effects on ... more »
    • Sidebar: Industry Experts Share Flow Cytometry I...
    • GEN recently spoke to several scientists with expertise in the flow cytometry arena about emerging trends and additional potential applications for this versatile research tool Clare Rogers, application scientist at Accuri Cytometers; Robert Balderas, vp, biological sciences at BD Biosciences; ... more »
  • Tutorials

    • Pooled Genome-Wide shRNA Screening
    • Heather Holemon
      Victoria Rusakova
    • RNA interference is an effective mechanism for gene silencing whereby double-stranded RNA triggers the cleavage and subsequent degradation of homologous transcript sequences In this evolutionarily conserved process, longer double-stranded RNA molecules are processed into shorter sequences (21–23 nucleotide small interfering ... more »
    • Analytical Considerations in Formulation
    • Sian Estdale, Ph.D.
    • Formulation is arguably the most critical—and challenging—component of biopharmaceutical drug development, second only to the molecule itself Formulation’s far-reaching consequences help sponsors satisfy the scientific, medical, and regulatory conditions for drug approval and, subsequently, support marketplace success... more »